GIRON, DANIELLE,HAMMERSCHMIDT, WALTER,PIECHON, PHILIPPE,POLASEK, JOHANNE,SCHREINER, ANDREAS,STOWASSER, FRANK
申请号：
NZ58782909
公开号：
NZ587829A
申请日:
2009.03.18
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed is a substantially pure crystalline anhydrous form II of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salt characterized by an x-ray powder diffraction pattern that shows maxima at 8.2, 11.8, 12.9, 13,8, 14.7, 16.6, 18.5, 20.3, 23.5 degrees, 2 theta. The crystalline form is useful for treating a disease which responds to an inhibition of VEGFR2 and FGFR3 activity, such as prostate cancer, colorectal cancer, breast cancer, multiple myeloma, pancreatic cancer, small cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, myeloproliferative disease, non-small cell leukemia, small cell leukemia, chronic lymphoid leukemia, sarcoma, melanoma, lymphoma, thyroid cancer, neuroendocrine cancer, renal cell cancer, gastric cancer, gastrointestinal stromal cancer, glioma, brain cancer, bladder cancer and cholangiocarcinoma.
